Genetic variant that raises ICP risk is protective against hepatitis B
A genetic variant unique to East Asians increases the risk of intrahepatic cholestasis of pregnancy (ICP) by more than 16 times, but it likely…
News
Lanifibranor improves liver health in MASH with diabetes in trial
Daily treatment with the investigational oral therapy lanifibranor — used alone or in combination with the diabetes medication Jardiance (empagliflozin) — led to improvements…
Stem-cell therapy during Kasai effective, safe in biliary atresia: Trial
Children with biliary atresia who received infusions of bone-marrow stem cells during a Kasai operation, a liver surgery that’s the main strategy for treating…
FDA grants breakthrough designation to hepatitis D treatment
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…
Livdelzi approved in UK as PBC treatment for certain adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary cholangitis (PBC), either in combination…
Bylvay, Kayfanda in EU, safely treats PFIC: Real-world study
In real-world use, Kayfanda (odevixibat) — available under the brand name Bylvay in the U.S. — lowered blood bile acid levels and eased…
IBAT inhibitors have potential to boost life quality for patients
Alagille syndrome comes with a high clinical, economic, and quality-of-life burden for patients and their families, but new treatments such as Livmarli (maralixibat)…
Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
Cour’s CNP-104 granted FDA orphan drug status for treating PBC
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CNP-104, Cour Pharmaceuticals’ treatment candidate for primary biliary cholangitis (PBC).
Maralixibat Phase 3 trial for cholestasis-related itch is enrolling
Enrollment is ongoing in a Phase 3 clinical trial that’s designed to evaluate Mirum Pharmaceuticals’ maralixibat for treatment-resistant itching, or pruritus, associated with rare…
Recent Posts
- Livmarli, Bylvay safely reduce pruritus in PFIC, Alagille children
- My son with liver disease will once again need to take vitamins
- Traffic pollution may increase risk of fatty liver disease: Mouse study
- Biliary atresia blood markers augur post-Kasai liver transplant need
- Virtual clinic for liver diseases opens to US patients